T-cell response to 3 doses of Sars-Cov2 BNT162b2 Pfizer vaccine in long term rituximab treated patients
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Internal Medicine"
DOI: 10.1016/j.ejim.2022.01.030
Abstract: B-depleting therapies increase the risk of severe COVID-19 [1] and have been shown to induce an impaired immune response to the SARS-COV2 vaccine [2]. There is a lack of data exploring the T-cell response to… read more here.
Keywords: response; sars cov2; rituximab treated; cell ... See more keywords